MedTrace Logo

Gelesis200 Safety and Tolerability Study and Effects on Glycemic and Appetite Parameters

NCT02652962 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-05-09

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of Gelesis200.

Conditions

  • Healthy Overweight Obese

Interventions

DEVICE

Gelesis200

3 capsules each containing 0.70 g

OTHER

Placebo

3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%

Sponsors & Collaborators

  • Gelesis, Inc.

    lead INDUSTRY

Principal Investigators

  • Audet · Quebec City, Quebec Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02652962 on ClinicalTrials.gov